Operational rules for the implementation of INN prescribing

International Journal of Medical Informatics

Volumn 83, Issue 1, 2014, Pages 47-56

  Van Bever, Elien ^a   Wirtz, Veronika J ^b   Azermai, Majda ^a   De Loof, Geert ^c   Christiaens, Thierry ^a,c,d   Nicolas, Luc ^e   Van Bortel, Luc ^a   Vander Stichele, Robert ^a  

^a GHENT UNIVERSITY   (Belgium)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c Belgian Centre for Pharmacotherapeutic Information (BCFI CBIP)   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e Federal Public Service for Health   (Belgium)

Author keywords

Belgium; Computerized prescription entry order; Drug Information Services; Electronic prescribing; International Nonproprietary Name (INN) prescribing; Nomenclature; Pharmacopoeias

Indexed keywords

BELGIUM; COMPUTERIZED PRESCRIPTION ENTRY ORDER; ELECTRONIC PRESCRIBING; INTERNATIONAL NONPROPRIETARY NAME (INN) PRESCRIBING; PHARMACOPOEIAS;

INFORMATION SERVICES; MEDICAL EDUCATION; TERMINOLOGY;

DATABASE SYSTEMS;

ALPRAZOLAM;

ARTICLE; BELGIUM; COMPUTERIZED PROVIDER ORDER ENTRY; DRUG INDUSTRY; DRUG INFORMATION; ELECTRONIC MEDICAL RECORD; ELECTRONIC PRESCRIBING; FACTUAL DATABASE; HUMAN; INTERNATIONAL NONPROPRIETARY NAME PRESCRIBING; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL PRACTICE; NATIONAL HEALTH SERVICE; NOMENCLATURE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE DATABASE; TREATMENT DURATION;

BELGIUM; COMPUTERIZED PRESCRIPTION ENTRY ORDER; DRUG INFORMATION SERVICES; ELECTRONIC PRESCRIBING; INTERNATIONAL NONPROPRIETARY NAME (INN) PRESCRIBING; NOMENCLATURE; PHARMACOPOEIAS;

BELGIUM; DRUG PRESCRIPTIONS; DRUGS, GENERIC; HEALTH PLAN IMPLEMENTATION; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84888427803     PISSN: 13865056     EISSN: 18728243     Source Type: Journal    
DOI: 10.1016/j.ijmedinf.2013.09.004     Document Type: Article

References (42)

1. World Health Organization (WHO). Guidance on INN [Website], 2012. Available from: (06.11.2012). http://www.who.int/medicines/services/inn/innguidance/en/index.html.
2. World Intellectual Property Organization (WIPO). Madrid System for the International Registration of Marks, 2012. Available from: (06.11.12). http://www.wipo.int/madrid/en/.
3. Think INN, prescribe INN, dispense INN: good professional practice. Prescrire International 2000, 9(50):184-190. (Epub. 2001/07/28. PubMed PMID: 11475502).
4. International Society of Drug Bulletins (I.S.B.D.) INN: an essential tool. In: I.S.B.D. Newsletter, 2006. pp. 1-17.
5. Vogler S., Schmickl B. Rational Use of Medicines in Europe 2010, Österreichisches Bundesinstitut für Gesundheitswesen, Vienna.
6. Koninklijk besluit houdende vaststelling van de modaliteiten inzake het voorschrift voor menselijk gebruik 2005.
7. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV/INAMI) Voorschrijven van geneesmiddelen: het aantal geneesmiddelen afgeleverd op stofnaamvoorschrift stijgt constant 2010, Available from: http://www.riziv.be/news/nl/press20100506.pdf.
8. Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG/AFMPS). Voorschrijven Op Stofnaam: Operationele regels voor het gebruik van het Voorschrijven Op Stofnaam in de medische praktijk en in het elektronisch medisch dossier, 2011. Available from: (14.06.13). http://www.fagg-afmps.be/nl/binaries/prescription-DCI-note-NL-2011-12-09_tcm290-97663.pdf.
9. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV/INAMI). Regels voor de voorschrijver bij VOS. Available from: (16.01.13). http://www.riziv.be/drug/nl/drugs/general-information/prescription/regulate_prescription.htm.
10. National Health Service (NHS). dm+d browser 2010. Available from: (06.11.12). http://www.ppa.org.uk/systems/pcddbrowserv2_3new/browser.jsp.
11. Heads of Medicines Agencies (HMA) Periodic Safety Update Report (PSUR) Synchronisation List 2011.
12. Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Current Medical Research and Opinion 2007, 23(5):953-960. (Epub. 2007/05/24. PubMed PMID: 17519062). 10.1185/030079907x182158.
13. National Prescribing Service (NPS) Change of Perindopril (Coversyl) Salt from Erbumine to Arginine 2006.
14. Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI/CBIP). Gecommentarieerd Geneesmiddelenrepertorium, 2012. Differences in potency between corticosteroids. Available from: (06.11.12). http://www.bcfi.be/GGR/Index.cfm?ggrWelk=/GGR/MPG/MPG_L.cfm.
15. World Health Organization (WHO). MedNet INN services, 2012. Available from: (06.11.12). http://mednet.who.int/SearchInn.aspx?c=1f216b1a-c080-46a1-9a39-c33717387926.
16. European Pharmacopeia. List of Standard Terms for Routes and Methods of Administration, 2012. Available from: (06.11.12). http://www.edqm.eu/StandardTerms/.
17. European Pharmacopeia. List of Standard Terms for Dosage Forms, 2012. Available from: (13.06.13). http://www.edqm.eu/StandardTerms/.
18. European Medicines Agency (EMA) Excipients in the Label and Package Leaflet of Medicinal Products for Human Use, 2001/83/EC 2003.
19. European Medicines Agency (EMA) Guideline on the Investigation of Bioequivalence 2010.
20. Health Canada Bioequivalence Requirements: Critical Dose Drugs 2006.
21. Food and Drug Administration (FDA). Code of Federal Regulations Title 21 2011. Available from: (06.11.12). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33.
22. Food Drug Administration (FDA) Guidance for Industry: Immediate Release Solid Oral Dosage Forms 1995.
23. Danish Health and Medicines Authority Bioequivalence and Labelling of Medicines with Regard to Generic Substitution 2012, Available from: http://www.dkma.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/marketing-authorisation/application-for-marketing-authorisation/bioequivalence-and-labelling-of-medicine--bstitution (06.11.12).
24. Goodman L.S., Hardman J.G., Limbird L.E., Gilman A.G., Hardman J.G., Limbird L., et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics 2001, McGraw-Hill.
25. Micromedex® Healthcare Series [Internet]. Thomson Reuters (Healthcare) Inc. 2006. Available from: (06.11.12). http://www.thomsonhc.com/.
26. MedlinePlus [Internet]. National Library of Medicine (US), 2005. Available from: (06.11.12). http://www.nlm.nih.gov/medlineplus/.
27. The International Association of Forensic Toxicologists (TIAFT). 2012. Available from: (06.11.12). http://www.tiaft.org/.
28. Sahoo N., Choudhury K., Manchikanti P. Manufacturing of biodrugs: need for harmonization in regulatory standards. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2009, 23(4):217-229. (Epub. 2009/08/25. PubMed PMID: 19697964). 10.2165/11317110-000000000-00000.
29. Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG/AFMPS). Voorschrijven op Stofnaam (VOS) en substitutie, 2012. Available from: (06.11.12). http://www.fagg-afmps.be/nl/MENSELIJK_gebruik/geneesmiddelen/geneesmiddelen/goed_gebruik_geneesmiddel/voorschrijven_op_stofnaam/.
30. Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG/AFMPS). Lijst met biologische geneesmiddelen beschikbaar op de markt in België 2012.
31. The referen ce database for electronic INN prescribing in Belgium [Internet], 2012. Available from: (06.11.12). http://www.bcfi.be/inn.
32. eHealth platform, 2012. Available from: (14.01.13). https://www.ehealth.fgov.be/.
33. France F.R. eHealth in Belgium, a new "secure" federal network: role of patients, health professions and social security services. International Journal of Medical Informatics 2011, 80(2):e12-e16. 10.1016/j.ijmedinf.2010.10.005.
34. Vrijens F., Van de Voorde C., Farfan-Portet M.I., Vander Stichele R. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care 2012, 13:315-325. (Epub. 2011/12/06. PubMed PMID: 22139141; PubMed Central PMCID: PMCPMC33433241). 10.1007/s10198-011-0367-2.
35. Farfan-Portet M.I., Van de Voorde C., Vrijens F., Vander Stichele R. Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care 2012, 13:301-313. (Epub. 2012/03/20. PubMed PMID: 22427042; PubMed Central PMCID: PMCPMC33433229). 10.1007/s10198-012-0377-8.
36. Denig P., Haaijer-Ruskamp F.M. Therapeutic decision making of physicians. Pharmaceutisch weekblad Scientific edition 1992, 14:9-15. (Epub. 1992/02/21. PubMed PMID: 15531253).
37. Denig P., Haaijer-Ruskamp F.M., Zijsling D.H. How physicians choose drugs. Social Science and Medicine (1982) 1988, 27(12):1381-1386. (Epub. 1988/01/01. PubMed PMID: 3238456).
38. Ammenwerth E., Schnell-Inderst P., Machan C., Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. Journal of the American Medical Informatics Association 2008, 15(5):585-600. 10.1197/jamia.M2667.
39. Kuperman G.J., Bobb A., Payne T.H., Avery A.J., Gandhi T.K., Burns G., et al. Medication-related clinical decision support in computerized provider order entry systems: a review. Journal of the American Medical Informatics Association 2007, 14(1):29-40. 10.1197/jamia.M2170.
40. Oliven A., Michalake I., Zalman D., Dorman E., Yeshurun D., Odeh M. Prevention of prescription errors by computerized, on-line surveillance of drug order entry. International Journal of Medical Informatics 2005, 74(5):377-386. 10.1016/j.ijmedinf.2005.03.010.
41. Koninklijk besluit houdende regeling van de slaapmiddelen en de verdovende middelen en betreffende risicobeperking en therapeutisch advies 1930.
42. Koninklijk besluit houdende regeling van sommige psychotrope stoffen en betreffende risicobeperking en therapeutisch advies 1998.